Navigation Links
Anacor to Present Clinical and Preclinical Data on Topical Anti-Inflammatory Candidates, AN2728 and AN2898, at the International Investigative Dermatology 2008 Conference
Date:5/8/2008

e treatment of toenail onychomycosis, which is a fungal infection of the nail and nail bed. Anacor entered into a worldwide license, development and commercialization agreement for AN2690 with Schering-Plough for all indications including the treatment of onychomycosis. Anacor also has a research and development collaboration with GlaxoSmithKline for the discovery, development, manufacture and worldwide commercialization of novel systemic therapeutics for viral and bacterial diseases utilizing Anacor's boron-based chemistry. For more information visit http://www.anacor.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the progress of our clinical trials and the safety and efficacy of our product candidates. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that could cause actual levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. Some factors that may affect these forward-looking statements include, but are not limited to, delays in the completion of our clinical trials, clinical failure at later stages of development and undesirable effects from our product candidates. These statements reflect the views of Anacor as of the date of this press release with respect to future events and, except as required by law, it undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this press release.


'/>"/>
SOURCE Anacor Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Anacor Files Registration Statement for Initial Public Offering
2. GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
3. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
4. Avicena Group to Present at Noble Financial Conference
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
7. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
8. CEL-SCI to Present at the Noble Financial Conference
9. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
10. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
11. Strategic Diagnostics Updates Roth Conference Presentation Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 2013 The Oklahoma tornado left ... ravage, the mayor of Moore, one of the heavily damaged ... a report from cnn.com. Reaching out to also be of ... and Safe Shield to counter the looming mold problem. , ... May 22, 2013, caused 24 deaths, My Cleaning Products shared. ...
(Date:5/23/2013)... , May 24, 2013 ... angefertigt – Bei der englischen ... , 91 % der Teilnehmer einer groß angelegten ... 20 % laut GINA [*] -Definition [1] als ... Menschen mit Asthma generell einer von vier Denkweisen zugeordnet ...
(Date:5/23/2013)... -- BioScrip, Inc. (NASDAQ: BIOS ) today announced ... Global Healthcare Conference to be held June 3-6, 2013 ... Richard Smith , President and Chief Executive ... Financial Officer, will present on Monday, June 3, 2013 ... About BioScrip BioScrip, Inc. provides comprehensive infusion and ...
(Date:5/23/2013)... Patheon Inc ., a leading ... global pharmaceutical industry, will host a complimentary webinar on ... on Tuesday, June 4, 2013 at 11 a.m. Eastern ... to comply with regulations for cleaning validation. Many ... underpinning and little evaluation of risk. Some companies ...
Breaking Biology Technology:Mayor of Oklahoma-Tornado-Impaired Town Proposes Storm Shelter Bill, My Cleaning Products Offers Complimentary Molderizer and Safe Shield to Help Victim with Looming Mold 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2
... January 6 Biopharmaceutical Company Kiadis,Pharma focused on ... field of bone marrow transplantation, announces today the ... (CMO). Dr. Egeler is a global,leading pediatric bone ... hemato-oncology. He brings,to Kiadis Pharma over more than ...
... Pa., Jan. 5 West Pharmaceutical Services, Inc. (NYSE: WST ... , CJS ... York City. The presentation is scheduled for 1:55pm on Wednesday, January 7, ... , Sidoti & ...
... Nektar Therapeutics,(Nasdaq: NKTR ) President and Chief ... the upcoming 27th Annual J.P. Morgan Healthcare,Conference in San ... 13, 2009 at 10:00 a.m. Pacific time (1:00 p.m. ... will be accessible via a Webcast through a link ...
Cached Biology Technology:Kiadis Pharma Appoints Dr. Maarten Egeler, MD PhD as Chief Medical Officer 2West to Present at Upcoming Conferences 2
(Date:5/24/2013)... and destruction by the immune system. Stimulation of the ... there are many factors that cause the immune system ... cells that function to suppress the immune system response. ... Investigation , researchers led by Ronald Levy at Stanford ... express proteins that can be targeted with therapeutic antibodies. ...
(Date:5/23/2013)... , Automated conserved noncoding sequence (CNS) discovery reveals ... , Within the genome of each species, there ... change in position and sequence over millions of years, ... these evolutionarily stable sequences, so-called conserved noncoding sequences (CNSs), ... or the condensation of chromosomes, but the function of ...
(Date:5/23/2013)... new mechanism by which estrogen suppresses lipid synthesis in ... new approach toward treating certain liver diseases. , ... they are changing long-held views in the field. Study ... journal Science Signaling . , "The dogma in ... that only receptors located in the nucleus respond to ...
Breaking Biology News(10 mins):Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2
... More than one in four elderly patients was given ... of a study by Ute Amann and her co-authors ... International ( Dtsch Arztebl Int 2012; 109[5]: ... can increase the risk of undesired drug effects, and ...
... of cardiovascular pathologies seem to have a higher cancer ... published in detail in the Archives of Internal ... supplementation with B vitamins has some benefits for protecting ... in recent years remain equivocal., The results of studies ...
... Hugh Ducklow, senior scientist and director of the ... to the U.S. Antarctic Program Blue Ribbon Panel. ... Holdren, director of the White House Office of Science ... National Science Foundation, is tasked with examining the status ...
Cached Biology News:Vitamin B and omega-3 supplementation and cancer: New data 2MBL's Hugh Ducklow appointed to Antarctic Blue Ribbon Panel 2
... with a molecular weight of 16 kDa. Leptin ... produced by adipocytes [1,2]. Leptin is thought to ... weight [1-3]. In the human, leptin levels are ... [4]. A relationship between serum leptin levels and ...
... We can introduce random mutations to the ... be then cloned into a vector of choice ... Mutation frequency can be set to a ... Number of clones 106-108. Mutations can be ...
Request Info...
... plasmid DNA preparations are prepared from ... from 1mg to multi-gram scales. Each ... needs, and glycerol stocks are maintained ... clonal selection (Clonal selection includes screening ...
Biology Products: